Recent FDA actions have created serious doubts about whether committee members are serving only the public interest and, as a result, industry biases now taint many advisory panel decisions, ... Today we took a giant step forward to squash those doubts.
Passage of this amendment to end conflicts of interest is a victory for public health and restores integrity and confidence in the FDA's advisory committees,